Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity

Elghandour, Ashraf; Sorady, Manal El; El-Rahman, Mohammed Z. Abd

doi:10.4081/hr.2009.e6

Cited by 19 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ElGhandour et al 72 studied H-FABP in 40 non-Hodgkin's lymphoma patients treated with 6 cycles of CT containing Doxorubicin (cumulative dose 300 mg/m 2 ). The authors concluded that H-FABP may serve as a reliable early marker for prediction of cardiomyopathy induced by Doxorubicin.…”

Section: Perspective Markers Of Ct-induced Cardiotoxicity (Under Study)mentioning

confidence: 99%

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Horáček¹,

Vašatová²,

Pudil³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. Cardiotoxicity is a well-known and potentially serious complication of anticancer therapy. Anthracyclinebased chemotherapy represents the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies. Methods and Results. Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome. Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. Increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have provided encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined. Conclusions. This review covers the current status of biomarkers for the early detection of anthracycline-induced cardiotoxicity. The authors present in brief, their own experience with multiple biomarkers in the detection of cardiotoxicity.

show abstract

Section: Perspective Markers Of Ct-induced Cardiotoxicity (Under Study)mentioning

confidence: 99%

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Horáček¹,

Vašatová²,

Pudil³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…Heart-type fatty acid binding protein (H-FABP) is also a small cytosolic protein released in the circulation after cardiac damage. It has been studied in chronic heart failure as a marker of ongoing myocardial damage [15] but only evaluated in one small study in the setting of cardiotoxicity [16].…”

Section: Introductionmentioning

confidence: 99%

Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors

et al. 2015

View full text Add to dashboard Cite

Introduction. Cardiotoxicity represents a major limitation for the use of anthracyclines or trastuzumab in breast cancer patients. Data from longitudinal studies of diastolic dysfunction (DD) in this group of patients are scarce. The objective of the present study was to assess the incidence, evolution, and predictors of DD in patients with breast cancer treated with anthracyclines.Methods. This analytical, observational cohort study comprised 100 consecutive patients receiving anthracycline-based chemotherapy (CHT) for breast cancer. All patients underwent clinical evaluation, echocardiogram, and measurement of cardiac biomarkers at baseline, end of anthracycline-based CHT, and at 3 months and 9 months after anthracycline-based CHT was completed. Fifteen patients receiving trastuzumab were followed with two additional visits at 6 and 12 months after the last dose of anthracycline-based CHT. A multivariate analysis was performed to find variables related to the development of DD. Fifteen of the 100 patients had baseline DD and were excluded from this analysis.

show abstract

“…In 40 patients treated with AC-containing CT, FABP levels were measured within 24 h after CT; patients with significant (under the normal limit of 50%) LVEF reduction had higher FABP levels compared to those without evidence of cardiac dysfunction [59]. Elevation in GPBB, but not in FABP, was reported by…”

Section: Elevated Tni (N=36)mentioning

confidence: 94%

Assessment of cardiotoxicity with cardiac biomarkers in cancer patients

Cardinale

Cipolla

2011

Herz

View full text Add to dashboard Cite

Cardiotoxicity remains a major limitation of chemotherapy, strongly affecting the quality of life and the overall survival of cancer patients, regardless of their oncologic prognosis. The time elapsed from the end of cancer therapy to the beginning of heart failure therapy for chemotherapy-induced cardiac dysfunction is an important determinant of the extent of recovery. This highlights the need for a real-time diagnosis of cardiac injury. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, precluding any chance of preventing its development. In the last decade, early identification, assessment, and monitoring of cardiotoxicity, by measurement of serum cardiospecific biomarkers, have been proposed as an effective alternative. In particular, the role of troponin I in identifying patients at risk for cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and cardiac events has clearly proved to be an effective strategy for this complication. In addition, novel biomarkers for the identification of cardiotoxicity are emerging. The use of a multimarker approach may provide a unique opportunity for advancement in this field, allowing for better stratification of the cardiac risk in cancer patients treated with anticancer drugs.

show abstract

Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity

Cited by 19 publications

References 21 publications

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors

Assessment of cardiotoxicity with cardiac biomarkers in cancer patients

Contact Info

Product

Resources

About